News | July 08, 2007

CCNY, Memorial Sloan-Kettering Receive $1.36 Million Breast Cancer Research Grant

July 9, 2007 – The U.S. Army Medical Research and Materiel Command Breast Cancer Research Program has granted $1.36 million over four years to The City College of New York (CCNY) and Memorial Sloan-Kettering Cancer Center (MSKCC) for the evaluation of near-infrared light’s use to detect and diagnose breast cancer and assess tumor aggressiveness.
“Our goal is to use near-infrared light to get images of tumors and try to determine whether they are malignant or benign,” said Swapan Gayen, professor of Physics and principal investigator for the project. “We also want to be able to distinguish between slow and fast-growing breast tumors, and assess how rapidly tumors are growing.”
Near-infrared light allows researchers to change the wavelength and color of the light to detect different types of molecules found in the breast, such as hemoglobin, lipids, proteins and water. “It’s essentially molecular spectroscopy, and it provides diagnostic potential,” said Gayen. “MRI can provide similar information, but it is more expensive and not readily available.”
According to CCNY, Gayen and his colleagues plan to construct a model breast with known tumors using tissue samples to determine if it can obtain an image, locate tumors and distinguish between tumor and normal tissue. They will then compare their findings to results from X-rays and MRI.
In order to measure the rate of tumor growth, the researchers will implant different types of known tumors in animal models and monitor their progress using conventional methods and near-infrared light, with the hope of conducting in vivo research in the future.
For more information: www. ccny.cuny.edu

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init